India, July 17 -- A new study has found a commonly prescribed anti-nausea medication is associated with better prognosis for women with early-stage breast cancer, particularly triple negative breast cancer.

The research team, co-led by Monash University and the Norwegian Institute of Public Health, evaluated Cancer Registry of Norway data of 13,811 women diagnosed with early-stage breast cancer between 2008 and 2020 who received both chemotherapy and anti-nausea medications that are used to prevent chemotherapy-induced nausea and vomiting.

In women with breast cancer, the use of the anti-nausea medication aprepitant during chemotherapy treatment was linked to an overall 11 per cent lower risk of developing cancer recurrence and 17 per c...